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endothelial integrity can inhibit SMC proliferation and
thus prevent intimal hyperplasia. An effective means to
induce endothelialization of vascular grafts or injured ves-
sels is likely to improve long-term patency. It could also
provide an alternative approach to the tissue engineering
strategy of in vitro generation of all layers of arterial wall,
which may be limited by the immunogenicity of endothe-
lial cells (ECs).
We have developed techniques to locally deliver
cytokines to vascular grafts and injured arteries with a
hydrogel-based delivery system. In previous work, we
applied fibroblast growth factor–1 (FGF-1) with heparin
onto canine aortoiliac and thoracoabdominal aortic
expanded polytetrafluoroethylene grafts with fibrin glue
(FG).1,2 The grafts impregnated with FG containing FGF-
1 and heparin exhibited enhanced endothelialization when
compared with FG-treated or untreated grafts. However,
a significant increase in intimal thickening was observed in
the FGF-1 treated specimens explanted after 20 weeks.
To date, an ideal cytokine for vascular application has
not been reported. Vascular endothelial growth factor
The development of intimal hyperplasia is a conse-
quence of smooth muscle cell (SMC) migration and pro-
liferation along with accumulation of extracellular matrix
and represents a primary failure mode after vascular inter-
vention. It has been suggested that the endothelium plays
an important role in maintaining the homeostasis of the
normal arterial wall and that the reestablishment of
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Objective: Cardiovascular tissue engineering approaches to vessel wall restoration have focused on the potent but rela-
tively nonspecific and heparin-dependent mesenchymal cell mitogen fibroblast growth factor 1 (FGF-1). We hypothe-
sized that linking FGF-1 to a sequence likely to bind to cell surface receptors relatively more abundant on endothelial
cells (ECs) might induce a relative greater EC bioavailability of the FGF-1. We constructed a heparin-binding growth-
associated molecule (HB-GAM)/FGF-1 chimera by linking full-length human HB-GAM to the amino-terminus of
human FGF-1β (21-154) and tested its activities on smooth muscle cells (SMCs) and ECs.
Methods: Primary canine carotid SMCs and jugular vein ECs were plated in 96-well plates in media containing 10% fetal
bovine serum and grown to approximately 80% confluence. After being growth arrested in serum-free media for 24
hours, the cells were exposed to concentration ranges of cytokines and heparin, and proliferation was measured with
tritiated-thymidine incorporation. Twenty percent fetal bovine serum was used as positive control, and phosphate-
buffered saline was used as negative control.
Results: In the presence of heparin the HB-GAM/FGF-1 chimera stimulated less SMC proliferation than did the wild-
type FGF-1 with a median effective dose of approximately 0.3 nmol versus approximately 0.1 nmol (P < .001). By con-
trast, the chimera retained full stimulating activity on EC proliferation with a median effective dose of 0.06 nmol for
both cytokines. Unlike the wild-type protein, the chimera possessed heparin-independent activity. In the absence of
heparin, the chimera induced dose-dependent EC and SMC proliferation at 0.06 nmol or more compared with the
wild-type FGF-1, which stimulated minimal DNA synthesis at 6.0-nmol concentrations.
Conclusions: The HB-GAM/FGF-1 chimera displays significantly greater and uniquely heparin-independent mitogenic
activity for both cell types, and in the presence of heparin it displays a significantly greater EC specificity. (J Vasc Surg
2001;33:554-60.)
(VEGF) has caused attention in the past because of its EC-
specific mitogenic and chemoattractant activities. How-
ever, the results are controversial when applied to animal
models.3-7 Most of the naturally occurring growth factors
are nonspecific mesenchymal cell mitogens such as FGF-1,
which has a potent proliferative effect on both SMCs and
ECs.8 In the attempt to achieve a potent mitogen with rel-
ative EC specificity, a series of FGF-1 mutants have been
established and tested in our laboratories.
Heparin-binding growth-associated molecule (HB-
GAM), also called pleiotrophin, is an 18-kd secreted protein
of 136 amino acids with a high affinity to heparin.9 It also
binds to transmembrane heparan sulfate-proteoglycan
(HS-PG) including syndecan-1, syndecan-3 (N-syndecan),
and syndecan-4 (ryudocan) with high affinity.10-12 We
hypothesized that syndecans are likely in relatively greatest
abundance on ECs, and therefore, an HB-GAM/FGF-1
chimeric construct would preferentially alter FGF-1
bioavailability to ECs versus SMCs by virtue of this altered
high affinity binding site density. Thus, we constructed an
HB-GAM/FGF-1 chimera by linking full-length human
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HB-GAM to the amino-terminus of human FGF-1β (21-
154) and tested its activities on SMCs and ECs.
MATERIALS AND METHODS
Materials. Chemicals and biologicals were obtained as
follows: oligonucleotide primer used for polymerase chain
reaction (PCR) was purchased from Bioserve (Laurel,
Md); TAQ polymerase from Perkin Elmer (Foster City,
Calif); Bluescript SK+ from Stratagene (La Jolla, Calif);
pET 3C and the Escherichia coli strain BL21(pLysS) from
Novagen (Madison, Wis); heparin Sepharose and S-
Sepharose from Pharmacia Biotech (Piscataway, NJ);
Vydac C18 4.6 × 220 mm from The Separations Group
(Hesperia, Calif); 0.05% trypsin/0.53 mmol/L EDTA
and collagenase from Gibco (Grand Island, NY);
fibronectin, human thrombin, FGF-1 from the American
Red Cross (Rockville, Md); thiopental sodium from
Abbott Laboratories (Morris Plains, NJ); bovine lung
heparin from Pharmacia and Upjohn (Kalamazoo, Mich);
anti–von Willebrand factor (vWF) antibody from Dako
Corp (Carpenteria, Calif); anti–α-actin antibody from
Fig 1. Proliferation of SMCs (A) and ECs (B) in response to various concentrations of wild-type FGF-1 (striped bar) and the HB-
GAM/FGF-1 chimera (solid bar) in absence of heparin expressed relative to 20% FBS positive control (mean ± SD). EC, Endothelial
cell; SMC, smooth muscle cell. 
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Sigma Chemical Company (St Louis, Mo); tritiated thymi-
dine from NEN Life Science Products (Boston, Mass);
and methanol, trichloroacetic acid, acetic acid, and scintil-
lation fluid from Fisher Scientific (Fair Lawn, NJ).
The media used were as follows: EC complete medium
consisted of M199 (Gibco), 10% fetal bovine serum (FBS)
(Hyclone, Logan, Utah), 100 U/mL penicillin and 100
µg/mL streptomycin (Gibco), FGF-1 5 ng/mL, and
heparin 5 U/mL; EC growth medium consisted of M199,
10% FBS, 100 U/mL penicillin, and 100 µg/mL strepto-
mycin; EC quiescent medium consisted of Iscove’s modi-
fied Dulbecco medium (Gibco), 2 mmol/L L-glutamine
(Gibco), 5.5 × 10-5 mmol/L 2-mecaptoethanol (Gibco),
5% bovine serum albumin (Sigma), insulin-transferrin-
selenium (insulin 10 µg/mL, transferrin 5.5 µg/mL, sele-
nium 0.0067 µg/mL; Gibco), 100 U/mL penicillin, and
100 µg/mL streptomycin; SMC growth medium con-
sisted of Dulbecco modified Eagle medium (DMEM)
(Gibco), 10% FBS, 10 mmol/L L-nonessential amino
acids (Gibco), 100 mmol/L sodium pyruvate (Gibco), 50
µg/mL gentamicin (Gibco), 100 U/mL penicillin, and
100 µg/mL streptomycin; and SMC quiescent medium
consisted of DMEM:F12 (Gibco), insulin 1 µmol/L
(Sigma), L-ascorbic acid 0.2 mmol/L (Sigma), transferrin
5 µg/mL (Sigma), 100 U/mL penicillin, and 100 µg/mL
streptomycin.
Construction, expression, and purification of the
HB-GAM/FGF-1 chimera. The chimera was con-
structed with an antisense primer (primer A: 5´-GAA GGT
GGT GAT TTC CCC TTC AGC ATC CAG CAT CCT
CTC CTG TTT CTT GCC-3´) designed to span the 5´
end of the FGF-1 open reading frame (ORF), and the 3´
end of the HB-GAM ORF. A hybrid complementary
DNA (cDNA) fragment was generated from the human
HB-GAM cDNA (gift of M. Jaye) by PCR with primer A
and a sense primer (primer B: 5´-AAT TCC ATA TGG
GGA AGA AAG AGA AAC CAG AAA AAA AAG TG-
3´). This PCR product consists of the ORF of HB-GAM
without the signal peptide sequence, and the first 24
nucleotides of the FGF-1 ORF are at its 3´ end. Another
fragment was generated by PCR with primers C: (5´-GCT
GAA GGG GAA ATC ACC ACC TTC-3´) and D: (5´-
CAA CAG AGA TCT TTA ATC AGA GGA GAC-3´) that
generated the ORF of FGF-1, excluding the initiator
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Fig 2. Proliferation of SMCs (A) and ECs (B) in response to various concentrations of wild-type FGF-1 (striped bar) and HB-
GAM/FGF-1 chimera (solid bar) in presence of 5 U/mL of heparin expressed relative to 20% FBS positive control (mean ± SD). EC,
Endothelial cell; SMC, smooth muscle cell.
methionine. These two fragments were combined in a sin-
gle PCR reaction with primers A and D. The resulting
cDNA product is a chimera of HB-GAM and FGF-1. The
chimera was subcloned into Bluescript SK+, and the
cDNA sequence was confirmed by dideoxy sequencing.
The chimera was excised from this plasmid and subcloned
into pET-3C for high-level protein expression.
The BL21-pLysS strain of E coli containing the pET-
3C/chimera construct was grown at 37°C to late log
phase, induced with 50 nmol isopropyl thiogalactose, and
incubated for an additional 16 hours at room temperature.
The cells were collected by centrifugation at 5000g for 10
minutes at 4°C. The supernatant was discarded, and the
cell pellet was frozen at –70°C. The cell pellet was thawed
and resuspended in 100 mmol/L Tris pH 7.4, 10
mmol/L EDTA, 100 mmol/L glucose, and DNA sheared
by sonication. The suspension was clarified of insoluble
debris by centrifugation at 10,000g for 10 minutes. The
chimera protein was purified by heparin-Sepharose affinity
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chromatography, ion-exchange chromatography on S-
Sepharose fast flow, and finally by reversed-phase chro-
matography on a Vydac C18 column.
EC and SMC harvest. Animal care complied with
The Guide for the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources, Commission
on Life Sciences, National Research Council, 1996) and
the Principles of Laboratory Animal Care (National
Institutes of Health publication no. 85-23, revised 1985).
Adult, mongrel dogs were anesthetized with thiopen-
tal sodium, intubated, and ventilated. Anesthesia was
maintained with nitrous oxide and halothane. Bilateral
neck incisions were made. For ECs, bilateral external jugu-
lar veins were removed, inverted, and processed per our
previously reported protocol.13 The veins were sequen-
tially placed into 0.05% trypsin/EDTA 0.53 mmol/L and
collagenase 100 U/mL at 37°C for 10 minutes each. After
the veins were discarded, the trypsin and collagenase solu-
tions were centrifuged, and the pellets were resuspended
A
B
Fig 3. Proliferation of SMCs (A) and ECs (B) in response to various concentrations of wild-type FGF-1 (striped bar) and HB-
GAM/FGF-1 chimera (solid bar) in presence of 50 U/mL of heparin expressed relative to 20% FBS positive control (mean ± SD). EC,
Endothelial cell; SMC, smooth muscle cell.
in EC complete medium. The ECs were plated onto a
fibronectin-coated T-25 culture flask (2.5 µg/cm2) and
incubated in a 37°C, 5% carbon dioxide chamber. The
media were changed every 2 to 3 days, and confluent cells
were passaged with trypsin-EDTA. EC identity was con-
firmed with immunofluorescent dual staining with vWF
and α-actin antibodies. Only ECs exhibiting 95% of posi-
tive vWF staining and 2% or less of α-actin staining were
used for the proliferation assays. ECs were used within
passages 1 through 3.
SMCs were obtained from canine carotid arteries by
means of our previously published explant technique.14
The carotid arteries were opened longitudinally, and the
intima and adventitia were removed by scraping and dis-
secting with a scalpel. The medial layer was minced and
placed into SMC growth media. Primary SMCs migrating
from the explants were used in all experiments. SMC iden-
tity was confirmed with immunofluorescent staining with
α-actin antibodies, and only cultures exhibiting 95% posi-
tive staining were used in the proliferation assays.
EC and SMC proliferation assays. ECs, at 10,000
cells per well, were plated into 96-well polystyrene plastic
plates (Becton Dickinson, Lincoln Park, NJ) in 200 µL of
EC growth medium and allowed to grow for 3 days until
the wells were approximately 80% confluent. The medium
was removed, the cells were washed with phosphate-
buffered saline (PBS), and 200 µl/mL of serum-free EC
quiescent media were placed on each well. After 24 hours
quiescence, 50 µL of test solution containing various con-
centrations of either FGF-1 or HB-GAM/FGF-1 chimera
plus various concentrations of heparin, diluted in PBS such
that the final concentration in the well was the stated value,
was placed on the wells. Fifty microliters per well of PBS
was used as negative control, and 50 µL per well of FBS was
used as positive control. After 48 hours, 1 µCi per well of
tritiated thymidine was placed on the wells, and the plates
were processed 24 hours later. To process, the medium was
removed, and the wells were washed with 0.9% saline. The
cells were fixed in 100% methanol for 10 minutes, lysed
with distilled water, and precipitated with 5% trichloroacetic
acid. The cell lysates were washed with distilled water, and
the DNA was solubilized by adding 100 µL of 0.3 mol/L
sodium hyroxide. This solution was placed into 10 mL of
scintillation fluid that contained 20 µL of acetic acid to
avoid opacification of the scintillation fluid with an accom-
panying dampening of the counts per minute.
For SMCs, the same protocol was used but with dif-
ferent growth and quiescent media. FGF-1 and HB-
GAM/FGF-1 chimera at 0.006 to 6 nmol ± heparin at 0,
5, or 50 U/mL was tested. There were five replicate wells
per each treatment. All experiments were repeated at least
three times with consistent results.
Statistics. Normalized data (percent of positive con-
trol = [counts per minute treatment/counts per minute
positive control] × 100%) were used to compare the dif-
ference between treatments. Because both positive and
negative control wells were repeated on all plates, this nor-
malization corrects for potential differences caused by the
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sequence of plate analysis or by the placement of the plates
within the incubator. At the level of α = .05, one-way
analysis of variance and Student-Newman-Keuls methods
(Sigmastat software 1.0, Chicago, Ill) were used to deter-
mine significance. General linear models procedure (SAS
system, Mountainview, Calif) was used to analyze the
dose-response curves.
RESULTS
There was approximately a sevenfold spread of tritium-
thymidine incorporation between the PBS (negative con-
trol) and the 20% FBS (positive control) on ECs with cpm
5809.54 ± 1368.35 versus 39932.78 ± 2718.94 and a 20-
fold spread on SMC (cpm 945.28 ± 126.39 vs 19399.95 ±
2475.46) data consistent in these proliferation assays in our
laboratory. The FGF-1 exhibited a heparin-dependent
property and a striking synergism with heparin, consistent
with our previous published studies.15,16
Unlike the wild-type protein, the HB-GAM/FGF-1
chimera displayed heparin-independent activity. In the
absence of heparin, the wild-type FGF-1 induced only
minimal DNA synthesis at concentrations as high as 6
nmol, whereas the HB-GAM/FGF-1 chimera elicited
dose-dependent DNA synthesis starting at 0.006 nmol on
both ECs and SMCs. At 6 nmol, the HB-GAM/FGF-1
chimera induced fourfold more proliferation than wild-
type FGF-1 on both ECs (63.16% ± 2.69% vs 13.14% ±
1.96%, P < .01) and SMCs (109.68% ± 5.11% vs 25.08%
± 0.71%, P < .01) (Fig 1).
The proliferative activities of both FGF-1 and the
chimera were potentiated by the addition of heparin. In
the presence of 5 U/mL of heparin, FGF-1 stimulated
dose-dependent cell proliferation maximally at 0.6 nmol,
giving 63.74% ± 3.08% of positive control on ECs and
119.35% ± 7.06% on SMCs (Fig 2). The chimera exhib-
ited less activity on SMCs with a median effective dose
(ED50) of approximately 0.3 nmol compared with approx-
imately 0.1 nmol for FGF-1 (P < .001). By contrast, the
chimera retained full stimulating activity on EC prolifera-
tion with a median effective dose of 0.06 nmol for both
cytokines. As the concentration of heparin increased to 50
U/mL, the overall response to both cytokines decreased
in SMCs but not in ECs (Fig 3).
DISCUSSION
Although a number of cytokines and growth factors have
been experimentally used to manipulate the healing process
after vascular procedures, an ideal factor is not currently avail-
able. FGFs have been intensively studied in part because of
their mitogenic potency. However, the mitogenic activities of
FGFs are relatively nonspecific, potentially causing concomi-
tant intimal hyperplasia. To manipulate the biological func-
tion of FGF-1, we have constructed a series of FGF-1
mutants, the HB-GAM/FGF-1 chimera among them.
HB-GAM is a neurotrophic factor functioning during
neuronal growth and development. The mitogenic activity
of this protein is controversial. We and others found that
HB-GAM purified from bovine brain was unable to stim-
ulate DNA synthesis or proliferation of BALB/c 3T3,
BALB/MK, NRK, and human umbilical vein ECs.9 The
recombinant protein expressed in a prokaryotic or bac-
culovirus system was not mitogenic,9,17,18 but transfection
of human cells with HB-GAM resulted in the appearance
of mitogenic activity and phenotypic transformation of the
transfected cells.17,19 The amino acid sequence of HB-
GAM is highly conserved among species (approximately
98% identity). Among the 136 amino acids after the cleav-
age of a 32 amino acid signal peptide, 21% is lysine result-
ing in an extremely basic molecule, and 10 disulfide-linked
cysteine residues form the backbone for the three-dimen-
sional structure.9 HB-GAM exhibits high affinity to
heparin and heparan sulfate and thus can be sequestered in
the extracellular compartment.20,21 By linking HB-GAM
to the FGF-1 molecule, we were able to change the
heparin dependency of FGF-1 and to obtain a relatively
EC-favored proliferative activity.
The proliferation effect of wild-type FGF-1 is heparin
dependent. It is suggested that heparin can stabilize the
FGF-1 molecular tertiary structure, prolong its biological
life, protect it from heat and acid inactivation, and prevent
proteolysis.22-24 Heparin or heparan sulfate functions as a
coreceptor facilitating FGF-1 receptor dimerization, which
is required for tyrosine kinase activation, c-fos messenger
RNA transcription, and cell proliferation.25 It appears that
the construction of the HB-GAM/FGF-1 chimera dimin-
ished the requirement for exogenous heparin. The mecha-
nisms responsible for this modification of FGF-1 function
remain to be elucidated. It is unlikely that HB-GAM will
trigger the signaling pathway for cell proliferation because
HB-GAM itself or combined separately with FGF-1 did
not show any proliferation effects on both cell types (data
not shown). It was demonstrated that HB-GAM could
bind to transmembrane HS-PGs on the cell surface such as
syndecan-1, syndecan-4, and especially N-syndecan, which
has been suggested to be an HB-GAM receptor/corecep-
tor.10 Unlike FGF-2, FGF-1 itself does not bind to N-syn-
decan,26 indicating that N-syndecan is not involved in the
conventional FGF-1 ligand/receptor interactions. The
HB-GAM/FGF-1 chimera structure might bring synde-
cans into the FGF-1 ligand/receptor interaction thus
changing its heparin dependency. However, heparin was
able to potentiate the proliferation effect of the HB-
GAM/FGF-1 chimera at the low-dose range.
In the presence of heparin, the HB-GAM/FGF-1
chimera retained full proliferative activity of FGF-1 on
ECs but exhibited less potency on SMCs. It was found
that the affinity of HB-GAM for heparin is higher than
that of FGF-2.20 In addition, the HB-GAM showed a
100-fold stronger binding affinity to immobilized heparin
than to soluble heparin.20 It is possible that the binding of
HB-GAM in the chimera to HS-PGs in the extracellular
matrix changed the availability of FGF-1 to ECs and
SMCs. Evidence suggests that proteoglycans on the cell
surface and in the extracellular matrix might differ quanti-
tatively and qualitatively between ECs and SMCs.27,28
HB-GAM–guided distribution of the chimera might
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account for the shifting of the proliferative activity of
FGF-1 between cell types.
VEGF is an EC-specific growth factor with chemoat-
tractant and angiogenic activities. Theoretically, it may be
more likely to induce endothelialization without causing
intimal hyperplasia. However, documented results have
been controversial. We have locally applied VEGF to 
balloon-injured canine carotid arteries with an FG delivery
system. It was found that FG/VEGF/heparin treatment
induced a VEGF-dependent intimal hyperplasia despite
non–VEGF-specific augmentation of reendothelialization
of the injured arteries, resulting from the delivery vehicle
itself.29 Although the effectiveness of the administration of
a bioactive protein needs to be carefully evaluated, the sec-
ondary effects induced by the protein in vivo should also
be taken into account. VEGF has no direct stimulating
effect on SMC proliferation, but it could induce ECs to
express platelet-derived growth factor and heparin-binding
epidermal growth factor–like growth factor. VEGF-stimu-
lated EC condition medium reportedly stimulates SMC
proliferation.30 The downstream events after the applica-
tion of a growth factor could be as important as its intrin-
sic activities for its ultimate effect when used in vivo. In the
vascular wall, ECs and SMCs interact with each other
either through direct contact or through paracrine mecha-
nisms. To try to manipulate one cell type might inevitably
affect the other. Potency and EC specificity would be crit-
ical for an in vivo–applied mitogen. We have focused on
FGF-1 because of its strong proliferative effect on ECs that
is 50 times that of the VEGF (unpublished data).
It is recognized that arterial and venous ECs may
respond somewhat differently to some agonists. In our
experiment we used venous ECs and arterial SMCs
because of their direct clinical relevance.
In conclusion, the HB-GAM/FGF-1 chimera displays
uniquely heparin-independent mitogenic activity for both
ECs and SMCs, and in the presence of heparin it displays
a relative EC specificity. This chimeric construct may pro-
vide a novel approach to engineering endothelialized sur-
faces without the concurrent fibroplastic reaction elicited
by wild-type FGF-1.
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